[1] |
Huang KW, Yang T, Xu JY, et al. Prevalence,risk factors,and management of asthma in China:a national cross-sectional study[J]. Lancet, 2019, 394(10196):407-418.
DOI
PMID
|
[2] |
中华医学会变态反应分会呼吸过敏学组(筹), 中华医学会呼吸病学分会哮喘学组. 中国过敏性哮喘诊治指南(第一版,2019年)[J]. 中华内科杂志, 2019, 58(9):636-655.
|
|
The Respiratory Allergy Group of Chinese Society of Allergy, The Asthma Group of Chinese Thoracic Society,Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of allergic asthma(2019,1st ed)[J]. Chin J Intern Med, 2019, 58(9):636-655.
|
[3] |
林江涛, 王文巧, 周新, 等. 我国30个省市城区门诊支气管哮喘患者控制水平的调查结果[J]. 中华结核和呼吸杂志, 2017, 40(7):494-498.
|
|
Lin JT, Wang WQ, Zhou X, et al. The level of asthma control in China from a national asthma control survey[J]. Chin J Tuberc Respir Dis, 2017, 40(7):494-498.
|
[4] |
奥马珠单抗治疗过敏性哮喘专家组, 中华医学会呼吸病学分会哮喘学组. 奥马珠单抗治疗过敏性哮喘的中国专家共识[J]. 中华结核和呼吸杂志, 2018, 41(3):179-185.
|
|
The Expert Group of Omalizumab Treatment of Allergic Asthma, The Asthma Group of Chinese Thoracic Society, Chinese Medical Association. Chinese expert consensus on omalizumab in the treatment of allergic asthma[J]. Chin J Tuberc Respir Dis, 2018, 41(3):179-185.
|
[5] |
蔡慧, 墨玉清, 薛小敏, 等. 真实世界奥马珠单抗治疗中重度过敏性哮喘的疗效及安全性[J]. 中华临床免疫和变态反应杂志, 2019, 13(3):199-204.
|
|
Cai H, Mo YQ, Xue XM, et al. Real-world study on efficacy and safety of omalizumab for treatment of moderate-to-severe asthma[J]. Chin J Allergy Clin Immunol, 2019, 13(3):199-204.
|
[6] |
朱力, 史冬雷, 王军, 等. 信息化采血登记平台的构建及应用[J]. 中华护理杂志, 2020, 55(3):383-386.
|
|
Zhu L, Shi DL, Wang J, et al. Construction and application of an informationized platform of blood collection[J]. Chin J Nurs, 2020, 55(3):383-386.
|
[7] |
孙玉娇, 史婷奇, 张宁, 等. 低血糖护理决策支持系统的设计及应用[J]. 中华护理杂志, 2020, 55(7):1028-1032.
|
|
Sun YJ, Shi TQ, Zhang N, et al. Design and application of hypoglycemia nursing decision support system[J]. Chin J Nurs, 2020, 55(7):1028-1032.
|
[8] |
中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(2016年版)[J]. 中华结核和呼吸杂志, 2016, 39(9):675-697.
|
|
The Asthma Group of Chinese Thoracic Society,Chinese Medical Association. Chinese guidelines for the prevention and treatment of asthma(2016 ed)[J]. Chin J Tuberc Respir Dis, 2016, 39(9):675-697.
|
[9] |
支凡, 王青, 杨永仕, 等. 奥马珠单抗注射治疗138例过敏性疾病患者的流程管理及安全性[J]. 中华临床免疫和变态反应杂志, 2020, 14(3):221-227.
|
|
Zhi F, Wang Q, Yang YS, et al. Retrospective study on process management and safety evaluation of omalizumab therapy among 138 patients[J]. Chin J Allergy Clin Immunol, 2020, 14(3):221-227.
|
[10] |
赵永信, 顾莺, 张晓波, 等. 住院患儿疼痛管理决策支持系统的构建与应用研究[J]. 中华护理杂志, 2020, 55(8):1147-1153.
|
|
Zhao YX, Gu Y, Zhang XB, et al. Construction and application of the decision support system for pain management in hospitalized children[J]. Chin J Nurs, 2020, 55(8):1147-1153.
|
[11] |
王红燕, 冯素文, 谢臻蔚, 等. 孕产妇盆底功能康复信息化管理平台的构建及应用[J]. 中华护理杂志, 2018, 53(7):801-805.
|
|
Wang HY, Feng SW, Xie ZW, et al. Construction and application of an information platform for rehabilitation of maternal pelvic floor function[J]. Chin J Nurs, 2018, 53(7):801-805.
|
[12] |
Campisi R, Crimi C, Intravaia R, et al. Adherence to omalizumab:a multicenter “real-world” study[J]. World Allergy Organ J, 2020, 13(2):100103.
DOI
URL
|
[13] |
施宇衡, 汤葳, 段玉香, 等. 上海地区成人哮喘患者治疗依从性的影响因素分析[J]. 国际呼吸杂志, 2019, 39(7):481-486.
|
|
Shi YH, Tang W, Duan YX, et al. Influence factors of treatment compliance in adult asthma patients in Shanghai[J]. Int J Respir, 2019, 39(7):481-486.
|